Is CMPX or BCAX more profitable?

Compass Therapeutics' return on equity of -38.71% beat Bicara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Compass Therapeutics N/A -38.71% -34.72% Bicara Therapeutics N/A -41.49% -38.59%

Does the media refer more to CMPX or BCAX?

In the previous week, Bicara Therapeutics had 5 more articles in the media than Compass Therapeutics. MarketBeat recorded 8 mentions for Bicara Therapeutics and 3 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.72 beat Bicara Therapeutics' score of 1.14 indicating that Compass Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bicara Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ABSI or CMPX?

In the previous week, Absci had 5 more articles in the media than Compass Therapeutics. MarketBeat recorded 8 mentions for Absci and 3 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.72 beat Absci's score of 1.26 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Absci 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is JBIO or CMPX more profitable?

Compass Therapeutics' return on equity of -38.71% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Jade Biosciences N/A -49.11% -45.62% Compass Therapeutics N/A -38.71% -34.72%

Does the media favor CMPX or VIR?

In the previous week, Vir Biotechnology had 7 more articles in the media than Compass Therapeutics. MarketBeat recorded 10 mentions for Vir Biotechnology and 3 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.72 beat Vir Biotechnology's score of 1.30 indicating that Compass Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Vir Biotechnology 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TRAX or CMPX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Compass Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A Compass Therapeutics N/A -38.71% -34.72%

Does the media favor TRAX or CMPX?

In the previous week, First Tracks Biotherapeutics and First Tracks Biotherapeutics both had 3 articles in the media. Compass Therapeutics' average media sentiment score of 1.72 beat First Tracks Biotherapeutics' score of 0.94 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment First Tracks Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Compass Therapeutics (CMPX) Competitors

$2.40 -0.12 (-4.76%)

As of 08/28/2026 04:00 PM Eastern

Compare

CMPX vs. BCAX, ABSI, JBIO, VIR, and TRAX

Should you buy Compass Therapeutics stock or one of its competitors? Compass Therapeutics's main competitors and comparable companies include Bicara Therapeutics (BCAX), Absci (ABSI), Jade Biosciences (JBIO), Vir Biotechnology (VIR), and First Tracks Biotherapeutics (TRAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Compass Therapeutics compare to Bicara Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Compass Therapeutics presently has a consensus target price of $11.77, indicating a potential upside of 390.38%. Bicara Therapeutics has a consensus target price of $32.64, indicating a potential upside of 39.29%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Compass Therapeutics is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

Compass Therapeutics' return on equity of -38.71% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-38.71%	-34.72%
Bicara Therapeutics	N/A	-41.49%	-38.59%

Compass Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.75, suggesting that its share price is 175% less volatile than the broader market.

68.4% of Compass Therapeutics shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Compass Therapeutics has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	508.49	-$66.49M	-$0.40	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

In the previous week, Bicara Therapeutics had 5 more articles in the media than Compass Therapeutics. MarketBeat recorded 8 mentions for Bicara Therapeutics and 3 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.72 beat Bicara Therapeutics' score of 1.14 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Bicara Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Therapeutics beats Bicara Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Compass Therapeutics compare to Absci?

Absci (NASDAQ:ABSI) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

52.1% of Absci shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 10.5% of Absci shares are owned by insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Absci has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

Compass Therapeutics has lower revenue, but higher earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	533.83	-$115.18M	-$0.80	N/A
Compass Therapeutics	$850K	508.49	-$66.49M	-$0.40	N/A

Absci currently has a consensus price target of $13.43, suggesting a potential upside of 54.17%. Compass Therapeutics has a consensus price target of $11.77, suggesting a potential upside of 390.38%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Compass Therapeutics has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Compass Therapeutics' return on equity of -38.71% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-7,756.38%	-61.71%	-54.52%
Compass Therapeutics	N/A	-38.71%	-34.72%

In the previous week, Absci had 5 more articles in the media than Compass Therapeutics. MarketBeat recorded 8 mentions for Absci and 3 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.72 beat Absci's score of 1.26 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Compass Therapeutics beats Absci on 13 of the 17 factors compared between the two stocks.

How does Compass Therapeutics compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

68.4% of Compass Therapeutics shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Compass Therapeutics had 2 more articles in the media than Jade Biosciences. MarketBeat recorded 3 mentions for Compass Therapeutics and 1 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.87 beat Compass Therapeutics' score of 1.72 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Jade Biosciences	Very Positive
Compass Therapeutics	Very Positive

Jade Biosciences has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

Jade Biosciences currently has a consensus target price of $51.75, suggesting a potential upside of 148.32%. Compass Therapeutics has a consensus target price of $11.77, suggesting a potential upside of 390.38%. Given Compass Therapeutics' higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Compass Therapeutics has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A
Compass Therapeutics	$850K	508.49	-$66.49M	-$0.40	N/A

Compass Therapeutics' return on equity of -38.71% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-49.11%	-45.62%
Compass Therapeutics	N/A	-38.71%	-34.72%

Summary

Compass Therapeutics beats Jade Biosciences on 10 of the 15 factors compared between the two stocks.

How does Compass Therapeutics compare to Vir Biotechnology?

Compass Therapeutics (NASDAQ:CMPX) and Vir Biotechnology (NASDAQ:VIR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Compass Therapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-38.71%	-34.72%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

In the previous week, Vir Biotechnology had 7 more articles in the media than Compass Therapeutics. MarketBeat recorded 10 mentions for Vir Biotechnology and 3 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.72 beat Vir Biotechnology's score of 1.30 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Vir Biotechnology	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compass Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market.

Compass Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. Compass Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	508.49	-$66.49M	-$0.40	N/A
Vir Biotechnology	$302.59M	6.06	-$437.99M	-$1.86	N/A

Compass Therapeutics currently has a consensus price target of $11.77, suggesting a potential upside of 390.38%. Vir Biotechnology has a consensus price target of $21.57, suggesting a potential upside of 99.18%. Given Compass Therapeutics' higher possible upside, research analysts clearly believe Compass Therapeutics is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Compass Therapeutics beats Vir Biotechnology on 9 of the 15 factors compared between the two stocks.

How does Compass Therapeutics compare to First Tracks Biotherapeutics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

First Tracks Biotherapeutics' return on equity of 0.00% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Compass Therapeutics	N/A	-38.71%	-34.72%

In the previous week, First Tracks Biotherapeutics and First Tracks Biotherapeutics both had 3 articles in the media. Compass Therapeutics' average media sentiment score of 1.72 beat First Tracks Biotherapeutics' score of 0.94 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
First Tracks Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

First Tracks Biotherapeutics has higher earnings, but lower revenue than Compass Therapeutics. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
Compass Therapeutics	$850K	508.49	-$66.49M	-$0.40	N/A

68.4% of Compass Therapeutics shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

First Tracks Biotherapeutics presently has a consensus price target of $63.00, suggesting a potential upside of 50.50%. Compass Therapeutics has a consensus price target of $11.77, suggesting a potential upside of 390.38%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Compass Therapeutics beats First Tracks Biotherapeutics on 10 of the 12 factors compared between the two stocks.

Get Compass Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPX vs. The Competition

Export

Metric	Compass Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$432.21M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-6.00	11.62	273.16	25.45
Price / Sales	508.49	1,295.87	605.06	76.64
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	2.61	16.53	12.98	6.14
Net Income	-$66.49M	-$22.80M	$3.48B	$348.86M
7 Day Performance	N/A	-0.31%	0.13%	-0.80%
1 Month Performance	23.71%	9.80%	7.08%	4.13%
1 Year Performance	-31.23%	55.66%	24.67%	15.17%

Compass Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMPX Compass Therapeutics	2.8722 of 5 stars	$2.40 -4.8%	$11.77 +390.4%	-31.2%	$432.21M	$850K	N/A	20	News Coverage
BCAX Bicara Therapeutics	2.3885 of 5 stars	$24.94 +2.7%	$32.40 +29.9%	+96.2%	$1.61B	N/A	N/A	32
ABSI Absci	2.8783 of 5 stars	$9.24 +0.7%	$13.43 +45.3%	+264.4%	$1.58B	$2.80M	N/A	210	Positive News Gap Down
JBIO Jade Biosciences	2.4159 of 5 stars	$23.45 -5.1%	$51.75 +120.7%	+163.8%	$1.57B	N/A	N/A	20	Positive News
VIR Vir Biotechnology	2.5592 of 5 stars	$9.39 +1.6%	$20.63 +119.6%	+119.2%	$1.56B	$68.56M	N/A	580	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMPX) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compass Therapeutics (CMPX) Competitors

CMPX vs. BCAX, ABSI, JBIO, VIR, and TRAX

How does Compass Therapeutics compare to Bicara Therapeutics?

Summary

How does Compass Therapeutics compare to Absci?

Summary

How does Compass Therapeutics compare to Jade Biosciences?

Summary

How does Compass Therapeutics compare to Vir Biotechnology?

Summary

How does Compass Therapeutics compare to First Tracks Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX vs. The Competition

Compass Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compass Therapeutics (CMPX) Competitors

CMPX vs. BCAX, ABSI, JBIO, VIR, and TRAX

How does Compass Therapeutics compare to Bicara Therapeutics?

Do analysts rate CMPX or BCAX?

Is CMPX or BCAX more profitable?

Which has more volatility and risk, CMPX or BCAX?

Do insiders & institutionals believe in CMPX or BCAX?

Which has better valuation and earnings, CMPX or BCAX?

Does the media refer more to CMPX or BCAX?

Summary

How does Compass Therapeutics compare to Absci?

Do institutionals & insiders hold more shares of ABSI or CMPX?

Which has more risk & volatility, ABSI or CMPX?

Which has better earnings and valuation, ABSI or CMPX?

Do analysts prefer ABSI or CMPX?

Is ABSI or CMPX more profitable?

Does the media prefer ABSI or CMPX?

Summary

How does Compass Therapeutics compare to Jade Biosciences?

Do insiders & institutionals hold more shares of JBIO or CMPX?

Does the media prefer JBIO or CMPX?

Which has more risk and volatility, JBIO or CMPX?

Do analysts recommend JBIO or CMPX?

Which has stronger valuation and earnings, JBIO or CMPX?

Is JBIO or CMPX more profitable?

Summary

How does Compass Therapeutics compare to Vir Biotechnology?

Is CMPX or VIR more profitable?

Does the media favor CMPX or VIR?

Which has more risk and volatility, CMPX or VIR?

Which has higher earnings and valuation, CMPX or VIR?

Do analysts rate CMPX or VIR?

Do institutionals and insiders hold more shares of CMPX or VIR?

Summary

How does Compass Therapeutics compare to First Tracks Biotherapeutics?

Is TRAX or CMPX more profitable?

Does the media favor TRAX or CMPX?

Which has stronger earnings & valuation, TRAX or CMPX?

Do insiders & institutionals have more ownership in TRAX or CMPX?

Do analysts prefer TRAX or CMPX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX vs. The Competition

Compass Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools